FindTrial
Sign In

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221490
Enrollment
Unknown
Registered
2011-06-24
Start date
2011-06-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

investigational material(s) Generic name etc : AIN457 INN of investigational material : Secukinumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for In

Sponsors

Novartis Pharma K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.

Exclusion criteria

Exclusion criteria: -Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate). -Current drug-induced psoriasis. -Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.

Design outcomes

Primary

MeasureTime frame
Efficacy of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis [ Time Frame: 12 weeks ]—

Secondary

MeasureTime frame
Efficacy of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis [ Time Frame: 52 weeks ]—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026